Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators. Goodin DS, et al. Among authors: beckmann k. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7. doi: 10.1136/jnnp-2011-301178. Epub 2011 Dec 21. J Neurol Neurosurg Psychiatry. 2012. PMID: 22193561 Clinical Trial.
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Hartung HP, et al. Among authors: beckmann k. J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5. J Neurol. 2015. PMID: 26239222 Free PMC article.
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study. Ebers GC, et al. Among authors: beckmann k. J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):907-12. doi: 10.1136/jnnp.2009.204123. Epub 2010 Jun 19. J Neurol Neurosurg Psychiatry. 2010. PMID: 20562430 Clinical Trial.
Interferon beta-1b treatment does not induce autoantibodies.
Polman CH, Kappos L, Dahlke F, Graf R, Beckmann K, Bogumil T, Pozzilli C, Thompson AJ; European Study Group on Interferon Beta-1b in SPMS. Polman CH, et al. Among authors: beckmann k. Neurology. 2005 Mar 22;64(6):996-1000. doi: 10.1212/01.WNL.0000154522.86947.86. Neurology. 2005. PMID: 15781815 Clinical Trial.
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; BEYOND Study Group. Goodin DS, et al. Among authors: beckmann k. Mult Scler. 2012 Feb;18(2):181-95. doi: 10.1177/1352458511418629. Epub 2011 Sep 27. Mult Scler. 2012. PMID: 21952094 Clinical Trial.
298 results